Decreasing potassium conductance--a possible mechanism of phasic coronary vasospasm.
Uchida
Y
Y
D015761:4-Aminopyridine / Q000031:analogs & derivatives*; D000077770:Amifampridine; D000631:Aminopyridines / Q000494:pharmacology; D000818:Animals; D002118:Calcium / Q000378:metabolism; D003329:Coronary Vasospasm / Q000209:etiology* / Q000378:metabolism / Q000473:pathology; D003331:Coronary Vessels / Q000473:pathology / Q000502:physiology; D004285:Dogs; D004874:Ergonovine / Q000031:analogs & derivatives / Q000494:pharmacology; D005260:Female; D006801:Humans; D006863:Hydrogen-Ion Concentration; D066298:In Vitro Techniques; D008253:Macaca mulatta; D008297:Male; D008564:Membrane Potentials / Q000187:drug effects; D009119:Muscle Contraction / Q000187:drug effects; D009126:Muscle Relaxation / Q000187:drug effects; D009131:Muscle, Smooth, Vascular / Q000187:drug effects / Q000502:physiology; D009206:Myocardium / Q000378:metabolism; D009536:Niacinamide / Q000031:analogs & derivatives / Q000494:pharmacology; D020108:Nicorandil; D009543:Nifedipine / Q000494:pharmacology; D011188:Potassium / Q000378:metabolism*; D013552:Swine; D019789:Tetraethylammonium; D013757:Tetraethylammonium Compounds / Q000494:pharmacology
D000631:Aminopyridines; D013757:Tetraethylammonium Compounds; D009536:Niacinamide; D020108:Nicorandil; D019789:Tetraethylammonium; D015761:4-Aminopyridine; D009543:Nifedipine; D000077770:Amifampridine; D011188:Potassium; D002118:Calcium; D004874:Ergonovine